Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SBFM 
Sunshine Biopharma Inc (SBFM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SBFM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.97% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.02M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.33 | 52 Weeks Range 1.17 - 3.59 | Updated Date 10/17/2025 |
52 Weeks Range 1.17 - 3.59 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -17.35% | Operating Margin (TTM) -10.55% |
Management Effectiveness
Return on Assets (TTM) -11.08% | Return on Equity (TTM) -25.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2483362 | Price to Sales(TTM) 0.28 |
Enterprise Value -2483362 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA -7.73 | Shares Outstanding 4555945 | Shares Floating 4553895 |
Shares Outstanding 4555945 | Shares Floating 4553895 | ||
Percent Insiders 3.17 | Percent Institutions 2.85 |
Upturn AI SWOT
Sunshine Biopharma Inc
Company Overview
History and Background
Sunshine Biopharma Inc. was founded in 2006. Initially focused on nutritional supplements, it shifted its focus to oncology drug development, specifically for pancreatic cancer and other cancer types.
Core Business Areas
- Oncology Drug Development: Focuses on the development of anti-cancer drugs, primarily targeting pancreatic cancer and other solid tumors. Their lead compound is Adva-27a, which is in preclinical stages. Also focused on mRNA based therapeutics.
- Nutritional Supplements: Historically involved in the development and sale of nutritional supplements, but this segment appears less active in recent years.
Leadership and Structure
Dr. Steve N. Slilaty serves as the CEO. The company has a small team focused on research and development and management.
Top Products and Market Share
Key Offerings
- Adva-27a: Adva-27a is the company's lead drug candidate, targeting pancreatic cancer. It's currently in preclinical development. Market share data is not applicable at this stage as the product is not yet approved or marketed. Competitors include companies developing pancreatic cancer therapies, such as Roche (RHHBY) and Eli Lilly (LLY).
- mRNA-based Therapeutics: Sunshine Biopharma is exploring mRNA-based therapeutics. Market share data is not applicable at this stage as the product is not yet approved or marketed. Competitors include companies developing mRNA-based therapies, such as Moderna (MRNA) and BioNTech (BNTX).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Oncology is a major area of focus, with significant unmet needs, particularly in pancreatic cancer. mRNA therapeutics is a newer and rapidly developing field.
Positioning
Sunshine Biopharma is a small, early-stage biotech company. Their competitive advantage, if any, would be based on the unique mechanism of action of their drug candidates, should they prove effective and safe.
Total Addressable Market (TAM)
The global pancreatic cancer therapeutics market is expected to reach billions of dollars. The overall market for cancer therapies is very large. Sunshine Biopharma is attempting to capture a small portion of this with its Adva-27a drug.
Upturn SWOT Analysis
Strengths
- Focus on pancreatic cancer, an area of high unmet need.
- Potential novel mechanism of action for Adva-27a.
- Exploration into innovative technologies such as mRNA-based therapeutics.
Weaknesses
- Early-stage development with high risk of failure.
- Limited financial resources.
- Small company size, potentially lacking expertise in all areas.
Opportunities
- Potential for partnerships with larger pharmaceutical companies.
- Successful clinical trials could lead to significant value creation.
- Expansion into other cancer types.
Threats
- Clinical trial failures.
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and delays.
- Difficulty raising capital.
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Eli Lilly (LLY)
- Moderna (MRNA)
- BioNTech (BNTX)
Competitive Landscape
Sunshine Biopharma faces significant disadvantages compared to larger pharmaceutical companies. It relies on innovation and novel science.
Growth Trajectory and Initiatives
Historical Growth: Growth is characterized by development of drug candidates and funding events, not by sales or revenue.
Future Projections: Future growth is highly dependent on successful clinical trial outcomes and the ability to secure funding.
Recent Initiatives: Recent initiatives include continued preclinical studies of Adva-27a and expansion into mRNA-based therapeutics.
Summary
Sunshine Biopharma is a very risky, early-stage biotech company focusing on pancreatic cancer. Its success hinges on the success of its drug candidates, particularly Adva-27a, in clinical trials. The company has limited resources and faces stiff competition from established pharmaceutical giants. Its strengths lie in its targeted approach and novel mechanism of action, if proven safe and effective. Investors should be highly cautious and understand the risks involved.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available information and may not be complete or accurate. Investing in biotechnology companies carries significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sunshine Biopharma Inc
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2009-10-30 | Chairman, President & CEO Dr. Steve N. Slilaty Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 52 | Website https://sunshinebiopharma.com |
Full time employees 52 | Website https://sunshinebiopharma.com | ||
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.